Real World Study of Oxycodone/Naloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pain

This study is a prospective, single-arm, multicenter, real-world study to evaluate effect of bowel function, analgesic effect, quality of life, and safety of Mimeixin® in Chinese patients with severe cancer pain.

Inclusion Criteria: * Age ≥ 18 years old, with a histological or pathological diagnosis of advanced cancer. * Be diagnosed with severe (NRS ≥ 7 points) cancer pain, requiring regular opioid therapy. * Diagnosed with OIC according to the Rome IV diagnostic criteria for OIC, with a BFI score ≥ 30. * Determined by the investigator to be eligible for treatment with oxycodone/naloxone sustained-release tablets. * Estimated survival period of more than 3 months. * Voluntarily sign an informed consent form. Exclusion Criteria: * Patients with contraindications to oxycodone/naloxone sustained-release tablets (including allergy to the active ingredients or any excipients of this product; severe respiratory depression accompanied by hypoxemia and/or hypercapnia; severe chronic obstructive pulmonary disease; pulmonary heart disease; severe bronchial asthma; paralytic ileus caused by non-opioid drugs; moderate to severe liver function impairment). * Patients with structural malformations of the gastrointestinal tract (such as intestinal obstruction, stenosis), other known gastrointestinal diseases/symptoms (including cancer metastasis to the digestive tract), or gastrointestinal digestion and absorption disorders. * Patients with language communication barriers, cognitive impairments or mental illnesses, intracranial metastasis of tumors with consciousness disorders, or consciousness disorders caused by other reasons. * Other situations that the investigator judges as unsuitable for inclusion in the study.